About: Combination Antifungal Therapy for Invasive Mold Infections Among Pediatric Patients with Hematological Malignancies: Data from A Real-Life Case-Series

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Combination Antifungal Therapy for Invasive Mold Infections Among Pediatric Patients with Hematological Malignancies: Data from A Real-Life Case-Series Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Combination Antifungal Therapy for Invasive Mold Infections Among Pediatric Patients with Hematological Malignancies: Data from A Real-Life Case-Series
Creator	Gori, Andrea Bandera, Alessandra Longhi, Benedetta Alagna, Laura Biffi, Stefano Colombini, Antonella Foresti, Sergio Rizzari, Carmelo Rovelli, Attilio Verna, Marta Gori, An-Drea Migliorino, Guglielmo Peri, Anna
topic	covid:5688f38645b50f19f5b36727b64e89bf73ad453c#this
Source	PMC
abstract	BACKGROUND: Invasive mold infections in children with hematological malignancies are associated with high mortality rates. The use of combination antifungal therapy in cases with a severe clinical course is increasing, although information on the efficacy and safety of this approach is limited. METHODS: We present a case series of 13 children affected by hemato-oncological disorders who received combination antifungal therapy for invasive mold infections at our center (Pediatric Hematology, San Gerardo Hospital, Monza, Italy) from 2011 to 2016, with the aim of describing their clinical characteristics, types of infections, treatment regimens, clinical outcomes, and treatment safety. Medical records were retrospectively reviewed in order to describe patients' characteristics. RESULTS: Combination antifungal therapy included liposomal amphotericin associated with caspofungin (5/13, 38.4%), voriconazole (5/13, 38.4%), or posaconazole (3/13, 23.1%). The 12-week treatment response rate was 69.2% (6/13 patients showed complete response, 3/13 partial response). The crude mortality was 30.7% (4/13): half was related to invasive mold infections (2/13, 15.38%) and half to disease progression (2/13, 15.38%). Overall, treatment was well tolerated, and we did not observe any permanent discontinuation of antifungals due to related side effects. CONCLUSIONS: In our experience, combination antifungal therapy seems to be a safe option in immunocompromised children with invasive mold infections. Well-designed studies are needed to confirm the safety of this approach and to better understand its efficacy in the pediatric setting.
has issue date	2019-09-05(xsd:dateTime)
bibo:doi	10.20411/pai.v4i2.299
bibo:pmid	31538132
has license	cc-by
sha1sum (hex)	5688f38645b50f19f5b36727b64e89bf73ad453c
schema:url	https://doi.org/10.20411/pai.v4i2.299
resource representing a document's title	Combination Antifungal Therapy for Invasive Mold Infections Among Pediatric Patients with Hematological Malignancies: Data from A Real-Life Case-Series
has PubMed Central identifier	PMC6742350
has PubMed identifier	31538132
schema:publication	Pathog Immun
resource representing a document's body	covid:5688f38645b50f19f5b36727b64e89bf73ad453c#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/5688f38645b50f19f5b36727b64e89bf73ad453c
is schema:about of	named entity 'safety' named entity 'Invasive' named entity 'CASE' named entity 'INVASIVE' named entity 'MOLD' named entity 'ANTIFUNGAL THERAPY' named entity 'BACKGROUND' named entity 'MORTALITY RATES' named entity 'SERIES' named entity 'PATIENTS' named entity 'COMBINATION' named entity 'INVASIVE' named entity 'PEDIATRIC' named entity 'HEMATOLOGICAL MALIGNANCIES' named entity 'DATA' named entity 'ANTIFUNGAL THERAPY' named entity 'SEVERE CLINICAL COURSE' named entity 'HEMATOLOGICAL MALIGNANCIES' named entity 'USE OF' named entity 'INFORMATION' named entity 'INCREASING' named entity 'LIMITED' named entity 'APPROACH' named entity 'INFECTIONS' named entity 'COMBINATION' named entity 'INFECTIONS' named entity 'ASSOCIATED WITH' named entity 'MOLD' named entity 'SAFETY' named entity 'EFFICACY' named entity 'LIFE' named entity 'REAL' named entity 'CHILDREN' named entity 'CASES' named entity 'HIGH' covid:arg/5688f38645b50f19f5b36727b64e89bf73ad453c named entity 'Pediatric Patients' named entity 'hematological malignancies' named entity 'AKI' named entity 'demographic characteristics' named entity 'clinical setting' named entity 'case series' named entity 'fluconazole' named entity 'malignancy' named entity 'fusariosis' named entity 'first-line' named entity 'blood cultures' named entity 'first-line' named entity 'antifungal treatment' named entity 'toxicity' named entity 'GGT' named entity 'combination therapy' named entity 'salvage therapy' named entity '7/10' named entity 'morbidity' named entity 'CNS' named entity 'combination therapy' named entity 'prophylaxis' named entity 'hemato' named entity 'CNS' named entity 'non-Hodgkin lymphoma' named entity 'hypokalemia' named entity 'Hematology' named entity 'immunocompromised' named entity 'prophylaxis' named entity 'antifungal' named entity 'steroids'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software